Cladribine: from the bench to the bedside – focus on hairy cell leukemia

REFERENCE

• Giblett ER, Anderson JE, Cohen F, Pollara B, Meuwissen HJ. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. Lancet 2,1067–1069 (1972).
   Google Scholar
• Carson DA, Wasson DB, Kaye J etal. Deoxycytidine kinase-mediated toxicity of deoxyadenosine analogs toward malignant human lymphoblasts in vitro and toward murine L1210 leukemia in vivo. Proc. Natl Acad. Sci. USA 77,6865–6869 (1980).
   Google Scholar
• Carson DA, Wasson DB, Taetle R, Yu A. Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes. Blood 62 (4), 737–743 (1983).
   Google Scholar
• Beutler E. Cladribine (2-chlorodeoxyadenosine) . Lancet 340, 952–956 (1992).
   PubMed Web of Science ®Google Scholar
• •Important review of cladribine, including background information and initial clinical applications.
   Google Scholar
• Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes. j Gun. Invest. 75(2), 377–383 (1985).
   Google Scholar
• Thomberry NA, Lazebnik Y. Caspases:enemies within. Science 281,1312–1316 (1998).
   PubMed Web of Science ®Google Scholar
• •Comprehensive review of apoptosis mechanisms.
   Google Scholar
• Leoni LM, Chao Q, Cottam HB etal Induction of an apoptotic program in cell-free extracts by 2-chloro-2 deoxyadenosine 5 --triphosphate and cytochrome c. Proc. Natl Acad. Sci. USA 95(16), 9567–9571 (1998).
   Google Scholar
• Ceruti S, Beltrami E, Matarrese P et al. A key role for caspase-2 and caspase-3 in the apoptosis induced by 2-chloro-2 --deoxy-adenosine (Cladribine) and 2-chloro-adenosine in human astrocytoma cells. Mal Pharmacol 63,1437–1447 (2003).
   Google Scholar
• Genini D, Adachi S, Chao Q etal. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. B/ooc/96(10), 3537–3543 (2000).
   Google Scholar
• Hartman WR, HentoshThe antileukemia drug 2-chloro-2--deoxyadenosine: an intrinsic transcriptional antagonist. Mal Pharmacol 65,227–234 (2004).
   PubMed Web of Science ®Google Scholar
• Carrera CJ, Yamanaka H, Piro LD, Lotz M,Carson DA. Profound toxicity of deoxyadenosine and 2-chlorodeoxyadenosine toward human monocytes in vitm and in vivo. Adv. Exp. Med. Biol. 253B, 219–225 (1989).
   Google Scholar
• Petzer AL, Bilgeri R, Zilian U et al. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. B/ooc/78(10), 2583–2587 (1991).
   Google Scholar
• Gorski A, Grieb P, Korczak-Kowalska G, Wierzbicki P, Stepien-Sopniewska B, Mrowiec T Cladribine: an inhibitor of human B- and T-cell activation in vitro. Immunopharmacology26(3), 197–202 (1993).
   PubMedGoogle Scholar
• Liliemark J, Juliusson G. On thepharmacokinetics of 2-chloro-2 deoxyadenosine in humans. Cancer Res. 51(20), 5570–5572 (1991).
   Google Scholar
• Carson DA, Wasson DB, Beutler E.Antileukemic and immunosuppressive activity of 2-chloro-2 --deoxyadenosine. Pox. Nat/Acad. Sci. USA 81,2232–2236 (1984).
   Google Scholar
• Liliemark J, Albertioni F, Hassan M,Juliusson G. On the bioavailability of oral and subcutaneous 2-chloro-2 deoxyadenosine in humans: alternative routes of administration. j Gun. Oncol 10, 1514–1518 (1992).
   Google Scholar
• Albertioni F, Juliusson G, Liliemark J.On the bioavalability of 2-chloro-2 deoxyadenosine. The influence of food and omeprazole. Eur. j Gun. Pharmacol 44(6), 579–582 (1993).
   Google Scholar
• Saven A, Cheung WK, Smith I et al. Pharmacokinetic study of oral and bolus intravenous 2-chlorodeoxyadenosine in patients with malignancy. j Gun. Oncol 14(3), 978–983 (1996).
   Google Scholar
• Shrek R, Donnelly J. Hairy cells in bloodlymphoreticular neoplastic disease and flagellated cells of normal lymph nodes. B/ooc/27,199 (1966) .
   Google Scholar
• Ewald 0. Die leukämischereticuloendotheliose. Deutsches Arch. Kiln. Med. 142,222-228 (1923).
   Google Scholar
• Bouroncle BA, Wiseman BK, Doan CA.Leukemic reticuloendotheliosis. Blood 1, 609–630 (1958).
   Google Scholar
• Goodman RG, Bethel JK, Saven A. Hairycell leukemia: an update. CI.117: Opin. Hematol 10,258–266 (2003).
   Google Scholar
• •Concentrates on the biology of hairy cell leukemia and reviews available therapeutic options.
   Google Scholar
• Golomb HM, Catovsky D, Golde DW. Hairy cell leukemia: a clinical review of 71 cases. Ann. Intern. Med. 89,677 (1978).
   Google Scholar
• Matutes E, Wotherspoon A, Catovsky D. The variant form of hairy-cell leukaemia. Best Pract. Res. Gun. Haematol 16(1), 41–56 (2003).
   Google Scholar
• Tetreault SA, Robbins BA, Saven A. Treatment of hairy cell leukemia-variant with cladribine. Leuk. Lymphoma 35, 347–354 (1999).
   PubMed Web of Science ®Google Scholar
• Piro LD, Miller WE, Carrera CJ,Carson DA, Beutler E. Hairy cell leukemia. N. Engl. Med. 317,901 (1987).
   PubMedGoogle Scholar
• Piro LD, Carrera CJ, Carson DA, Beutler E. Lasting remissions in hairy cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl. I Med. 322,1117-1121 (1990).
   Google Scholar
• •Initial report of 12 hairy cell leukemia patients treated with cladribine.
   Google Scholar
• Saven A, Burian C, Koziol JA,LD.Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. B/ooc/92(6), 1918–1926 (1998).
   Google Scholar
• ••Provides data on a large, single-institutioncohort of hairy cell leukemia patients treated with cladribine.
   Google Scholar
• Goodman GR, Burian C, Koziol JA,Saven A. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. j Gun. Oncol 21(5), 891–896 (2003).
   Google Scholar
• ••Report on a subset of cladribine-treatedhairy cell leukemia patients with the longest follow-up information.
   Google Scholar
• Tallman MS, Hakimian D, Rademaker AW etal Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. B/ooc/88(6), 1954-1959 (1996).
   Google Scholar
• Hoffman MA, Janson D, Rose E, Rai KR.Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.j Gun. Oncol 15,1138–1142 (1997).
   Google Scholar
• Cheson BD, Sorensen JM, Vena DA etal Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C Protocol Mechanism of the National Cancer Institute: a report of 979 patients. Clin. Oncol 16(9), 3007–3015 (1998).
   Google Scholar
• Estey EH, Kurzrock R, Kantarjian HM etal Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood 79(4), 882–887 (1992).
   Google Scholar
• Dearden CE, Matutes E, Hilditch BL etal Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. BE j Haematol 106,515–519 (1999).
   PubMed Web of Science ®Google Scholar
• Jehn U, Bard R, Dietzfelbinger H etal Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann. Hematol 78(3), 139–144 (1999).
   Google Scholar
• Zinzani PL, Magagnoli M, Bendandi M et al. Long-term follow-up of hairy cell leukemia patients treated with 2-chlorodeoxyadenosine. I-Lematologica 85(9), 922–925 (2000).
   Google Scholar
• Robak T, Blasinska-Morawiec M, Blonski J etal 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur JI-Lematol. 62, 49–56 (1999).
   PubMed Web of Science ®Google Scholar
• Van Rohr A, Schmitz SF, Tichelli A etal Treatment of hairy cell leukemia with cladribine (2-chlorodeoxyadenosine) by subcutaneous bolus injection: a Phase II study. Ann. Oncol 13(10), 1641–1649 (2002).
   Google Scholar
• Saven A, Burian C, Adusumalli J, Koziol JA.Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. B/ooc/93(8), 2471–2477 (1999).
   Google Scholar
• Seymour JF, Kurzrock R, Freireich EJ,Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte count in patients with hairy cell leukemia. Blood 83(10), 2906–2911 (1994).
   Google Scholar
• Juliusson G, Liliemark J. Rapid recoveryfrom cytopenia in hairy cell leukemia after treatment with 2-chloro-2 --deoxyadenosine (CdA): relation to opportunistic infections. B/ooc/79(4), 888–894 (1992).
   Google Scholar
• Juliusson G, Lenkei R, Liliemark J.Flow cytometry of blood and bone marrow cells from patients with hairy cell leukemia: phenotype of hairy cells and lymphocyte subsets after treatment with 2-chlorodeoxyadenosine. Blood 83(12), 3672–3681 (1994).
   Google Scholar
• Kurzrock R, Strom SS, Estey E etal Second cancer risk in hairy cell leukemia: analysis of 350 patients. j Clin. Oncol 15(5), 1803–1810 (1997).
   Google Scholar
• Au WY, Klasa RJ, Gallagher R, Le N,Gascoyne RD, Connors JM. Second malignancies in patients with hairy cell leukemia in British Columbia: a 20-year experience. B/ooc/92 (4), 1160–1164 (1998).
   Google Scholar
• Cheson BD, Vena DA, Barrett J, Freidlin B.Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. j Clin. Oncoll7 (8), 2454–2460 (1999).
   Google Scholar
• Ries LA, Miller BA, Hankey BF etal SEER Cancer Statistics Revierg 1973–1991: Tables and Graphs. National Cancer Institute, MD, USA, National Institute of Health Publication No. 94–2789 (1994).
   Google Scholar
• Bernstein L, Newton P, Ross RK.Epidemiology of hairy cell leukemia in Los Angeles County. Cancer Res. 50, 3605–3609 (1990).
   Google Scholar
• Federico M, Zinzani PL, Frassoldati A etal Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. j Clin. Oncol 20(3), 638–646 (2002).
   Google Scholar
• Kluin-Nelemans JC, Kester MG,Melenhorst JJ etal Persistent clonal excess and skewed T-cell repertoire in T-cells from patients with hairy call leukemia. Blood 87, 3795–3802 (1996).
   PubMed Web of Science ®Google Scholar
• Van de Corput L, Falkenburg JH,Kluin-Nelemans JC. T-cell dysfunction inhairy cell leukemia: an updated review. Leuk. Lymphoma 30,31–39 (1998).
   PubMed Web of Science ®Google Scholar
• •Provides a detailed review of immune system alterations in hairy cell leukemia.
   Google Scholar
• Filleul B, Delannoy A, Ferrant A etal A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. Leukemia 8 (7), 1153–1156 (1994).
   Google Scholar
• Ellison DJ, Sharpe RVV, Robbins BA etal Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. B/ooc/84(12), 4310–4315 (1994).
   Google Scholar
• Wheaton S, Tallman MS, Hakimian D,Peterson L. Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2 -chlorodeoxyadenosine. Blood 87 (4), 1556–1560 (1996).
   Google Scholar
• Spiers AS, Moore D, Cassileth PA.Remissions in hairy-cell leukemia with pentostatin (2 --deoxycoformycin). N Engl. Med. 316,825-830 (1987).
   Google Scholar
• Saven A, Piro LD. Complete remissions inhairy cell leukemia with 2-chlorodeoxyadenosine after failure with2 --deoxycoformycin. Ann. Intern. Med. 119(4), 278–283 (1993).
   Google Scholar
• Flinn IW, Kopecky KJ, Foucar MK etal Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. B/ooc/96(9), 2981–2986 (2000).
   Google Scholar
• Cassileth PA, Cheuvart B, Spiers AS etal Pentostatin induces durable remissions in hairy cell leukemia. j Clin. Oncol 9, 243–246 (1991).
   PubMed Web of Science ®Google Scholar
• Nieva J, Bethel K, Saven A. Phase II studyof rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 102 (3), 810–813 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas DA, O'Brien S, Bueso-Ramos C etal Rituximab in relapsed or refractory hairy cell leukemia. Blood102 (12), 3906–3911 (2003).
   PubMed Web of Science ®Google Scholar
• Kreitman RJ, Wilson WH, Robbins D etal Responses in refractory hairy cell leukemia to a recombinant immunotoxin. B/ooc/ 94(10), 3340–3348 (1999).
   Google Scholar
• Kreitman RJ, Wilson WH, Bergeron K etal Efficacy of the antiCD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. Med. 345(4), 241–247 (2001).
   Google Scholar
• Piro LD, Carrera CJ, Beutler E,Carson DA. 2-chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. B/ood72(3), 1069–1073 (1988).
   Google Scholar
• Saven A, Carrera CJ, Carson DA,Beutler E, Piro LD. 2-chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia. Leuk. Lymphoma 5 (Suppl.), 133–138 (1991).
   Google Scholar
• Kawasaki H, Carrera CJ, Piro LD, Saven A, Kipps TJ, Carson DA. Relationship of deoxycytidine kinase and cytoplasmic 5 --nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine. Blooc181(3), 597–601 (1993).
   Google Scholar
• Juliusson G, Elmhom-Rosenborg A,Liliemark J. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl. I Med. 327,1056-1061 (1992).
   Google Scholar
• Juliusson G, Liliemark J. High completeremission rate from 2-chloro-2--deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. Clin. Onco1.11(4), 679–689 (1993).
   Google Scholar
• Saven A, Lemon RII, Piro LD. 2-chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl. I Med. 328,812-813 (1993).
   Google Scholar
• O'Brien S, Kantarjian H, Estey E etal Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. N Engl. I Med. 330, 319–322 (1994).
   Google Scholar
• Saven A, Lemon RII, Kosty M, Beutler E,Piro LD. 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. j Clin. Oncol 13(3), 570–574 (1995).
   Google Scholar
• Robak T, Blonski JZ, Kasznicki M.Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. Blood 96(8), 2723–2729 (2000).
   PubMed Web of Science ®Google Scholar
• Kay AC, Saven A, Carrera CJ et al. 2-chlorodeoxyadenosine treatment of low-grade lymphomas. J. Clin. Oncol 10(3), 371–377 (1992).
   Google Scholar
• Saven A, Emanuele S, Kosty M, Koziol J,Ellison D, Piro L. 2-chlorodeoxyadenosine activity in patients with untreated, indolent non-Hodgkin's lymphoma. Blooc186(5), 1710–1716 (1995).
   Google Scholar
• Jager G, Neumeister P, Brezinschek R et al Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a Phase II study. J. Clin. Oncol 20(18), 3872–3877 (2002).
   Google Scholar
• Armitage JO, Tobinai K, Hoelzer D,Rummel MJ. Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. mt. j Hematol 79(4), 311–321 (2004).
   Google Scholar
• Nabhan C, Gartenhaus RB, Tallman MS. Purine nucleoside analogs and combination therapies in B-cell chronic lymphocytic leukemia: dawn of a new era. Leuk. Res. 28(5), 429–442 (2004).
   Google Scholar
• Saven A, Carrera CJ, Carson DA, Beutler E,Piro LD. 2-chlorodeoxyadenosine: an active agent in the treatment of cutaneous T-cell lymphoma. B/ooc/80(3), 587–592 (1992).
   Google Scholar
• O'Brien S, Kurzrock R, Duvic M et al 2-chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders. B/ooc/84(3), 733–738 (1994).
   Google Scholar
• Kuzel TM, Hurria A, Samuelson E et al Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. B/ooc/87(3), 906–911 (1996).
   Google Scholar
• Tobinai K, Uike N, Saburi Y et al. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. Int. Hematol 77(5), 512–517 (2003).
   Google Scholar
• Dimopoulos MA, Kantarjian H, Estey E et al Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann. Intern. Med. 118(3), 195–198 (1993).
   Google Scholar
• Hampshire A, Saven A. Update of bolusadministration of cladribine in the treatment of Waldenstrom's macroglobulinemia. Blood 102 (11), 402a (2003).
   Web of Science ®Google Scholar
• Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrorris macroglobulinemia. Semin. Oncol 30(2), 243–247 (2003).
   Google Scholar
• Saven A, Piro LD, Lemon RII et al. Complete hematologic remissions in chronic-phase, Philadelphia-chromosome-positive, chronic myelogenous leukemia after 2-chlorodeoxyadenosine. Cancer 73(12), 2953–2963 (1994).
   Google Scholar
• Santana VM, Mirro J, Kearns C,Schell MJ, Crom W Blaldey RL. 2-chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia. J. Clin. Oncol 10(3), 364–370 (1992).
   Google Scholar
• Krance RA, Hurwitz CA, Head DR et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J. Clin. Oncol 19(11), 2804–2811 (2001).
   Google Scholar
• Holowiecki J, Grosicki S, Robak T etal Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, Phase III study. Leukemia 18, 989–997 (2004).
   Google Scholar
• Saven A, Kawasaki H, Carrera CJ etal 2-chlorodeoxyadenosine dose escalation in nonhematologic malignancies. J. Clin. Oncol 11 (4), 671–678 (1993).
   Google Scholar
• Hampshire AP, Saven A. Update ofcladribine in the treatment of adults with Langerhans-cell histiocytosis (LCH). Proc. Am. Soc. Clin. Oncol 23,581 (2004).
   Google Scholar
• Egeler RM, Favara BE, van Meurs M,Laman JD, Claassen E. Differential in situ cytokine profiles of Langerhans-like cells and T-cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94(12), 4195–4201 (1999).
   PubMed Web of Science ®Google Scholar
• Nicolaou F, Teodoridis JM, Park H et al CD11c gene expression in hairy cell leukemia is dependent upon activation of the proto-oncogenes ms and junD. Blood 101(10), 4033–4041 (2003).
   Google Scholar